| All Releases |
|---|
 |
Osiris Therapeutics Provides Update Regarding the Genzyme/Sanofi Relationship
02-09-12
11.3 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), today provided an update on the
status of the development and commercialization agreement with Genzyme,
a Sanofi company. On Wednesday, February 8, 2012, Sanofi issued a press
release, which included an update on their R&D pipelin...
|
|
Osiris Therapeutics Provides Update on Groundbreaking Stem Cell Trial for Type 1 Diabetes
01-03-12
14.1 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), today provided an update on its
Phase 2 trial evaluating Prochymal, a formulation of adult mesenchymal
stem cells (MSCs), in patients with newly diagnosed type 1 diabetes.
This first-of-its kind trial, conducted in partnership wit...
|
|
Osiris Therapeutics to Present at the 23rd Annual Piper Jaffray Healthcare Conference
11-22-11
12.1 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in inflammatory and cardiovascular disease areas and wound healing,
announced today that C. Randal Mills, Ph.D., President and ...
|
|
Osiris Therapeutics Reports Third Quarter 2011 Financial Results
11-04-11
27.7 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in inflammatory and cardiovascular disease areas and wound healing,
announced today its results for the third quarter ended Sep...
|
|
Osiris Therapeutics Announces Third Quarter 2011 Financial Results Conference Call
10-28-11
13.2 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will
report its financial results for the third quarter ended September 30,
2011, on Friday, November 4, 2011. C. Randal Mills, Ph.D., President and
Chief Executive Officer, and Philip R. Jacoby, Jr., Chief ...
|
|
Osiris Therapeutics to Present at the Sixth Annual JMP Securities Healthcare Conference
09-21-11
12.1 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in inflammatory and cardiovascular disease areas and wound healing,
announced today that Stephen Potter, Senior Vice President ...
|
|
Osiris Therapeutics to Present at 2011 UBS Global Life Sciences Conference
09-15-11
12.1 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in inflammatory and cardiovascular disease areas and wound healing,
announced today that C. Randal Mills, Ph.D., President and ...
|
|
Osiris Therapeutics to Present at 2011 Wedbush Securities Life Sciences Conference
08-11-11
12.1 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in inflammatory and cardiovascular disease areas and wound healing,
announced today that C. Randal Mills, Ph.D., President and ...
|
|
Osiris Therapeutics Reports Second Quarter 2011 Financial Results
08-05-11
28.3 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in inflammatory and cardiovascular disease areas and wound healing,
announced today its results for the second quarter ended Ju...
|
|
Osiris Therapeutics Announces Second Quarter 2011 Financial Results Conference Call
07-29-11
13.1 KB
|
| |
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will
report its financial results for the second quarter ended June 30, 2011,
on Friday, August 5, 2011. C. Randal Mills, Ph.D., President and Chief
Executive Officer, and Philip R. Jacoby, Jr., Chief Financ...
|
|
Board of Directors
Press Releases